Drug intelligence / Profile preview

DehydraTECH Testosterone

Development stage: Preclinical
Lead developer: Cannabis Delivery Sciences
Modality: Small Molecules
Administration: Oral

Overview

DehydraTECH Testosterone is an oral small molecule formulation of testosterone developed by Cannabis Delivery Sciences, a subsidiary of Lexaria Bioscience Corp. The drug utilizes the proprietary DehydraTECH drug delivery platform, which associates testosterone with fatty acid-rich triglyceride oils at a molecular level to enhance oral bioavailability and absorption while bypassing significant first-pass liver metabolism. By targeting the androgen receptor, DehydraTECH Testosterone is intended to treat hormone-related conditions such as hypogonadism. The program is currently in the preclinical stage of development.

Other names: Testosterone

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on DehydraTECH Testosterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DehydraTECH Testosterone.

Explore the full profile